Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 8/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 8/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509726 | 0.87 | MAPK8 (0.47) | MAPK8MAPK10MAOBMAPK13MAPK12 | |
| SCHEMBL25340487 | 0.87 | MAPK8 (0.47) | MAPK8MAPK10MAOBMAPK13MAPK12 | |
| SCHEMBL25340267 | 0.85 | NR3C1 (0.55) | NR3C1PGR | |
| SCHEMBL27074850 | 0.78 | NR3C1 (0.55) | NR3C1PGR | |
| SCHEMBL30728999 | 0.77 | NR3C1 (0.61) | NR3C1PGR | |
| SCHEMBL27075101 | 0.77 | NR3C1 (0.61) | NR3C1PGR | |
| SCHEMBL25340132 | 0.77 | SCN9A (0.43) | MAPK8MAPK10NR3C1MAOAMAOB | |
| SCHEMBL27074705 | 0.76 | HSD17B1 (0.42) | NR3C1PGRMAPK1 | |
| SCHEMBL30729083 | 0.76 | SCN9A (0.45) | MAPK8MAPK10NR3C1MAOAMAOB | |
| SCHEMBL27074700 | 0.76 | SCN9A (0.45) | MAPK8MAPK10NR3C1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
| CN-116744918-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4221702-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022072512-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | MAPK8 3308/4885MAPK10 3319/4885NR3C1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.